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Results: Successful reperfusion was achieved with tailored
thrombolytic therapy in all patients. Only one patient had rein-
farction on the 3rd day, for which she received another half-dose
Tenectaplase. She remained asymptomatic subsequently. 2 pa-
tients had IV site ecchymosis; no patient had major bleeding. All
the patients had one month follow-up and were asymptomatic.
Conclusion: Tailored thrombolytic therapy in very elderly pa-
tients, many of whom also have high bleeding risk factors, is
effective as well as safe. With the increasing lifespan, the number
of very elderly patients with STEMI is going to increase in the
future, posing a challenge of bleeding risk vs benefit with reper-
fusion strategies; tailored thrombolytic therapy would have
greater relevance in the future and needs to be studied in larger
number of patients.
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Background: Inflammation has been widely acknowledged to
contribute throughout all stages of atherogenesis. At present none
of the anti-cytokine therapy has a specific place in standard
therapeutic regimen for management of CAD. The project aims at
controlling the low grade systemic inflammation in CAD using
Sulfasalazine to improve overall disease outcome.
Methods: 50 eligible subjects (M/F¼43/7) meeting the inclusion/
exclusion criteria for CAD and low grade systemic inflammation,
were randomly assigned to once daily drug (n¼25, mean age¼
57.33±1.52 years) or placebo (n¼25, mean age¼58.58+2.16 years)
tablets (500 mg) for six months along with the previously
continued treatment regimen in all subjects. Assessment was
carried out at baseline, 12 week and subsequently after 24 weeks
of treatment. Various measures like, (a) hsCRP (b) Endothelial-
dependent Flow Mediated dilatation (FMD) of the brachial artery,
(c) Carotid artery IMT and artery stiffness index (Young’ elastic
Modulus), d) Hb, TLC, DLC, SGOT & SGPT, and creatinine were
evaluated. Student’s t-test (p<0.05) was used.
Results: hsCRP declined to (1.12±0.07 vs. 2.40±0.20mg/l, p<0.01),
SBP (118.20±3.11 vs. -128.95±4.19 mmHg, p¼0.04), carotid IMT
(0.68±0.02 vs. 0.79±0.01 mm (p<0.01) and carotid stiffness to 9.73
±0.91 vs. 15.87±3.11 mmHg.mm (p¼0.06) from baseline in drug
group as compared to placebo group, respectively. FMD improved
to 18.31±1.52 vs. 11.72±1.36% in drug group as compared to pla-
cebo group, (p¼0.02), whereas endothelium-independent vasodi-
lation with nitroglycerin (17.76±0.1.27 vs. 17.91± 1.41%; p¼0.94)
remained unchanged in both the groups. Moreover, safety
markers were with-in the normal range in both the groups
(p>0.05).
Conclusions: Thus, it is concluded that Sulfasalazine may act as
novel adjuvant therapeutic approach along with other standard
therapies for the management of CAD due to its effectiveness in
improving the endothelial dysfunction, reducing inflammation
and carotid stiffness.
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Background: Cardiovascular disease is the leading cause of death
worldwide and a majority of these deaths are attributable to
Myocardial infarction. Due paramountcy was given to evaluate
the correlation between the acute phase reactants and the
severity of acute coronary syndrome. One marker which was
under great a deliberation for long was fibrinogen. Albeit thorough
research, the association was debated till recently when many of
the western studies showed a correlation. None of the studies
were done on Indian population.
Objective: To study the correlation between serum fibrinogen
level (SFL) and severity of ACS.
Methods: This is a prospective study on hospitalized patients with
ACS. ACS was diagnosed based on clinical presentation, ECG and
cardiac biomarkers. Blood for fibrinogen was drawn at admission
and was measured by chemiluminescence technique. Coronary
angiography was performed through the femoral artery access
and the angiograms were evaluated by interventional cardiolo-
gists who will be blinded to the study. The severity of ACS was
assessed by Gensini score. Data analysis and interpretation was
done with SPSS 20. The statistical significance of association was
assessed by chi square test and p value of less than 0.05 was
considered significant.
Results: We serially analysed 91 patients presenting with ACS
from February 2014 to April 2014. 29 patients were excluded as per
pre-specified criteria. SFL was plotted against Gensini score in the
remaining 62 patients. Pearson’s correlation coefficient between
SFL and Gensini score was r¼0.869. We have found a significant
correlation between SFL and Gensini score with a significant p
value (<0.05).
Conclusion: Statistically significant correlation exists between SFL
and Gensini score. Higher SFLwere associatedwith higher Gensini
score. We hence conclude to say that serum fibrinogen can be
used to assess the severity of ACS.
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Background: India has a large number of deaths occurring due to
premature CAD, resulting from major risk factors like deranged
lipids. Familial Hypercholesterolemia (FH) is characterized by
isolated high levels of total and LDL cholesterol. It is an autosomal
dominant trait and is highly under recognized entity which if
diagnosed and treated early can prevent deaths due to CAD.
Methods: We enrolled 85 subjects suspected of FH: high total and
LDL cholesterols (>95thcentile), family history of hypercholester-
olemia and premature CAD. Molecular analysis was carried out in
three candidate genes: LDLR, fragment of exon 26 and 29 of ApoB
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